Szabó Attila Ádám, Enyedi Enikő Edit, Pintér Tamás Bence, Mányiné Ivetta Siket, Váradi Csongor, Bányai Emese, Tóth Attila, Papp Zoltán, Fagyas Miklós
Division of Clinical Physiology, Department of Cardiology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.
Kálmán Laki Doctoral School of Biomedical and Clinical Sciences, University of Debrecen, 4032 Debrecen, Hungary.
Biomedicines. 2025 Oct 16;13(10):2528. doi: 10.3390/biomedicines13102528.
: Urinary angiotensin-converting enzyme (uACE) activity has long been regarded as a promising biomarker for kidney and cardiovascular diseases; however, its clinical applicability has been limited by the presence of endogenous urinary inhibitors and technically demanding assay protocols. We aimed to establish a fast and reproducible method for measuring uACE activity to identify the inhibitory compounds responsible for previous assay failures and to define practical preanalytical conditions suitable for routine laboratory implementation. : A fluorescence-based kinetic assay was optimized for urine samples. Endogenous inhibitors were isolated by membrane filtration and chemically characterized, while the effect of sample dilution was evaluated as a simplified alternative for eliminating inhibitory interference. We assessed the stability of ACE activity under various storage conditions to support reliable measurement. : Urea (IC = 1.18 M), uric acid (IC = 3.61 × 10 M), and urobilinogen (IC = 2.98 × 10 M) were identified as the principal reversible inhibitors, jointly accounting for up to 90% suppression of uACE activity. Their inhibitory effect was effectively eliminated by a 128-fold dilution. ACE activity remained stable for 24 h at 25 °C but was completely lost after freezing. A strong positive correlation between uACE activity and creatinine concentration (r = 0.76, < 0.0001) justified normalization. ACE activity-to-creatinine ratio turned out to be significantly lower in ACE inhibitor-treated patients than in untreated controls (6.49 vs. 36.69 U/mol, < 0.0001). : Our findings demonstrate that accurate measurement of uACE activity is feasible using a rapid dilution-based protocol. The normalized ACE activity can serve as a practical biomarker for detecting pharmacological ACE inhibition and monitoring therapy adherence in cardiovascular care and may also provide insight into renal pathophysiology such as tubular injury or local RAAS-related processes.
长期以来,尿血管紧张素转换酶(uACE)活性一直被视为肾脏和心血管疾病的一种有前景的生物标志物;然而,其临床应用受到内源性尿抑制剂的存在以及技术要求较高的检测方案的限制。我们旨在建立一种快速且可重复的方法来测量uACE活性,以识别导致先前检测失败的抑制性化合物,并确定适合常规实验室实施的实际分析前条件。:针对尿液样本优化了基于荧光的动力学检测方法。通过膜过滤分离内源性抑制剂并进行化学表征,同时评估样品稀释的效果作为消除抑制干扰的简化替代方法。我们评估了ACE活性在各种储存条件下的稳定性,以支持可靠的测量。:尿素(IC = 1.18 M)、尿酸(IC = 3.61 × 10 M)和尿胆原(IC = 2.98 × 10 M)被确定为主要的可逆抑制剂,共同导致uACE活性抑制高达90%。通过128倍稀释可有效消除它们的抑制作用。ACE活性在25°C下可稳定24小时,但冷冻后会完全丧失。uACE活性与肌酐浓度之间存在强正相关(r = 0.76,< 0.0001),证明了标准化的合理性。结果表明,接受ACE抑制剂治疗的患者的ACE活性与肌酐比值明显低于未治疗的对照组(6.49对36.69 U/mol,< 0.0001)。:我们的研究结果表明,使用基于快速稀释的方案准确测量uACE活性是可行的。标准化的ACE活性可作为一种实用的生物标志物,用于检测心血管护理中药物性ACE抑制并监测治疗依从性,还可能为肾病理生理学提供见解,如肾小管损伤或局部肾素 - 血管紧张素 - 醛固酮系统(RAAS)相关过程。